

Ref no: 165291118
From: Commercial
Date: 29/11/18
Subject: Biologics and Biosimilar prescribing.

REQUEST

I have a Freedom of Information request with regards to the usage of Biologics and Biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last 12 months (latest 12 months possible) with the following drugs;

Number of patients treated	Rheumatoid Arthritis	Ankylosing Spondylitis	Psoriatic Arthritis	Psoriasis	Crohn's Disease	Ulcerative Colitis
TOTAL						
Abatacept (Orencia)						
Adalimumab (Biosimilar)						
Adalimumab (Humira)						
Apremilast (Otezla)						
Baricitinib (Olumiant)						
Brodalumab (Kyntheum)						
Certolizumab (Cimzia)						
Dimethyl Fumarate (Skilarence)						
Etanercept (Enbrel)						
Etanercept Biosimilar (Benepali or Erelzi)						

Golimumab (Simponi)						
Guselkumab (Tremfya)						
Infliximab (Remicade)						
Infliximab Biosimilar (Inflectra, Remsima or Flixabi)						
Ixekizumab (Taltz)						
Rituximab (Mabthera)						
Rituximab Biosimilar (Rixathon or Truxima)						
Sarilumab (Kevzara)						
Secukinumab (Cosentyx)						
Tildrakizuma b (Ilumetri)						
Tocilizumab (Ro Actemra)						
Tofacitinib (Xeljanz)						
Ustekinumab (Stelara)						
Vedolizumab (Entyvio)						

RESPONSE

The pharmacy system does not record the condition for which a patient is being treated so we are unable to provide information on the numbers of patients being treated for specific indications